TY - JOUR
T1 - Endovascular Treatment
T2 - The Role of Dominant Caliber M2 Segment Occlusion in Ischemic Stroke
AU - Compagne, Kars C. J.
AU - van der Sluijs, Pieter M.
AU - van den Wijngaard, Ido R.
AU - Roozenbeek, Bob
AU - Mulder, Maxim J. H. L.
AU - van Zwam, Wim H.
AU - Emmer, Bart J.
AU - Majoie, Charles B. L. M.
AU - Yoo, Albert J.
AU - Nijeholt, Geert J. Lycklama A.
AU - Lingsma, Hester F.
AU - Dippel, Diederik W. J.
AU - van der Lugt, Aad
AU - van Es, Adriaan C. G. M.
AU - Roos, Yvo B. W. E. M.
AU - van Oostenbrugge, Robert J.
AU - Boiten, Jelis
AU - Vos, Jan Albert
AU - Jansen, Ivo G. H.
AU - Mulder, Maxim J. H. L.
AU - Goldhoorn, Robert-Jan B.
AU - Schonewille, Wouter J.
AU - Majoie, Charles B. L. M.
AU - Coutinho, Jonathan M.
AU - Wermer, Marieke J. H.
AU - van Walderveen, Marianne A. A.
AU - Staals, Julie
AU - Hofmeijer, Jeannette
AU - Martens, Jasper M.
AU - Nijeholt, Geert J. Lycklama A.
AU - Boiten, Jelis
AU - Emmer, Bart J.
AU - de Bruijn, Sebastiaan F.
AU - van Dijk, Lukas C.
AU - van der Worp, H. Bart
AU - Lo, Rob H.
AU - van Dijk, Ewoud J.
AU - Boogaarts, Hieronymus D.
AU - de Kort, Paul L. M.
AU - Peluso, Jo J. P.
AU - van den Berg, Jan S. P.
AU - Postma, Alida A.
AU - Groot, P. F. C.
AU - MR CLEAN Registry Investigators
N1 - Funding Information:
The MR CLEAN Registry was partly funded by Toegepast Wetenschappelijk Instituut voor Neuromodulatie (TWIN) Foundation, Erasmus MC University Medical Center, Maastricht University Medical Center, and Amsterdam University Medical Center.
Funding Information:
Erasmus MC received funds from Dutch Heart Foundation, Brain Foundation Netherlands, the Netherlands Organisation for Health Research and Development, Health Holland Top Sector Life Sciences & Health, AngioCare BV, Medtronic/Covidien/EV3, AC Gmbh/LAMEPRO, Penumbra Inc, Top Medical/Concentric, Stryker, Stryker European Operations BV, Thrombolytic Science, LLC, for research by Drs Dippel, van der Lugt, and Emmer. Amsterdam Medical Center received funds from Stryker for consultations by Dr Majoie, Maastricht University Medical Center received funds from Stryker and Cerenovus for consultations by Dr van Zwam. Dr Yoo reports research grants form Penumbra Inc and Neuravi Inc, received consultant fees from Cerenovus/Johnson & Johnson, and has equity ownership in Insera Therapeutics Inc. Dr Majoie received research grants European Commission (paid to institution) and is a shareholder at Nico.lab B.V. (company that focuses on use of artificial intelligence for medical image analysis). The other authors report no conflicts.
Publisher Copyright:
© 2019 Lippincott Williams and Wilkins. All rights reserved.
PY - 2019/2
Y1 - 2019/2
N2 - Background and Purpose-It is unclear whether endovascular treatment (EVT) is beneficial for patients with acute ischemic stroke with occlusion of the M2 segment of the middle cerebral artery. We aimed to compare functional outcomes, technical aspects, and complications of EVT between patients with acute ischemic stroke because of M2 and M1 occlusions in clinical practice. Furthermore, outcome and complications after EVT in dominant and nondominant caliber M2 division occlusions were studied.Methods-Data were obtained from the MR CLEAN Registry (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands) which is an ongoing observational study in 16 Dutch centers performing EVT in the Netherlands. Functional outcome was measured with the modified Rankin Scale score at 90 days. Neurological recovery (delta National Institutes of Health Stroke Scale), successful reperfusion rates (extended Thrombolysis in Cerebral Infarction >= 2B), and safety outcomes were also investigated. Associations between occlusion location and outcome were analyzed with ordinal logistic regression models, with adjustment for other prognostic factors.Results-In total, 244 (24%) patients with an M2 and 759 (76%) patients with an M1 occlusion who underwent EVT were analyzed. Functional outcomes were not significantly different between patients with M2 versus M1 occlusions (adjusted common odds ratio, 1.24; 95% CI, 0.87-1.73). Occurrence of symptomatic intracerebral hemorrhage was also similar for M2 and M1 occlusions (6.6% versus 5.9%; P=0.84). Further analysis about dominance of an M2 branch was performed in 175 (72%) patients. Neurological recovery was comparable (mean delta National Institutes of Health Stroke Scale, -2 +/- 10 for dominant M2, -5 +/- 5 for nondominant M2, and -4 +/- 9 [P=0.24] for M1 occlusions). Furthermore, the effect of reperfusion status on functional outcome was comparable between occlusion divisions (common odds ratio, 1.27; 95% CI, 1.06-1.53 for dominant M2; common odds ratio, 1.32; 95% CI, 0.93-1.87 for nondominant M2; and common odds ratio, 1.35; 95% CI, 1.24-1.46 for M1 occlusions).Conclusions-Outcomes and complication rates after EVT were similar in patients with M2 and M1 occlusions. Although based on observational data and a limited sample size, a similar association of reperfusion status with functional outcome for all subgroups provides no evidence that patients with either a dominant or a nondominant M2 occlusion should be routinely excluded from EVT.
AB - Background and Purpose-It is unclear whether endovascular treatment (EVT) is beneficial for patients with acute ischemic stroke with occlusion of the M2 segment of the middle cerebral artery. We aimed to compare functional outcomes, technical aspects, and complications of EVT between patients with acute ischemic stroke because of M2 and M1 occlusions in clinical practice. Furthermore, outcome and complications after EVT in dominant and nondominant caliber M2 division occlusions were studied.Methods-Data were obtained from the MR CLEAN Registry (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands) which is an ongoing observational study in 16 Dutch centers performing EVT in the Netherlands. Functional outcome was measured with the modified Rankin Scale score at 90 days. Neurological recovery (delta National Institutes of Health Stroke Scale), successful reperfusion rates (extended Thrombolysis in Cerebral Infarction >= 2B), and safety outcomes were also investigated. Associations between occlusion location and outcome were analyzed with ordinal logistic regression models, with adjustment for other prognostic factors.Results-In total, 244 (24%) patients with an M2 and 759 (76%) patients with an M1 occlusion who underwent EVT were analyzed. Functional outcomes were not significantly different between patients with M2 versus M1 occlusions (adjusted common odds ratio, 1.24; 95% CI, 0.87-1.73). Occurrence of symptomatic intracerebral hemorrhage was also similar for M2 and M1 occlusions (6.6% versus 5.9%; P=0.84). Further analysis about dominance of an M2 branch was performed in 175 (72%) patients. Neurological recovery was comparable (mean delta National Institutes of Health Stroke Scale, -2 +/- 10 for dominant M2, -5 +/- 5 for nondominant M2, and -4 +/- 9 [P=0.24] for M1 occlusions). Furthermore, the effect of reperfusion status on functional outcome was comparable between occlusion divisions (common odds ratio, 1.27; 95% CI, 1.06-1.53 for dominant M2; common odds ratio, 1.32; 95% CI, 0.93-1.87 for nondominant M2; and common odds ratio, 1.35; 95% CI, 1.24-1.46 for M1 occlusions).Conclusions-Outcomes and complication rates after EVT were similar in patients with M2 and M1 occlusions. Although based on observational data and a limited sample size, a similar association of reperfusion status with functional outcome for all subgroups provides no evidence that patients with either a dominant or a nondominant M2 occlusion should be routinely excluded from EVT.
KW - middle cerebral artery
KW - reperfusion
KW - stroke
KW - thrombectomy
KW - treatment outcome
KW - MIDDLE CEREBRAL-ARTERY
KW - MECHANICAL THROMBECTOMY
KW - ANGIOGRAPHY
KW - OUTCOMES
KW - SCORE
KW - THERAPY
KW - M1
U2 - 10.1161/STROKEAHA.118.023117
DO - 10.1161/STROKEAHA.118.023117
M3 - Article
SN - 0039-2499
VL - 50
SP - 419
EP - 427
JO - Stroke
JF - Stroke
IS - 2
ER -